Monoclonal Ig deposition disease (MIDD) is a clonal plasma cell dyscrasia in which light-chain and/or heavychain subunits of Igs form non-fibrillar deposits in various tissues, causing organ dysfunction. 1 Kidneys are universally affected, often presenting with proteinuria and rapidly progressing to end-stage renal failure in more than 60% of cases.
1 Extra-renal manifestations are less common, but can include restrictive cardiomyopathy, myocardial infarction from coronary deposition of Igs, cholestatic jaundice, hepatic failure, cerebral infarction and hemorrhage, adrenal insufficiency, peripheral neuropathy, mononeuritis multiplex, and soft tissue deposition.
1,2 High-dose melphalan (HDM) and autologous SCT (auto-SCT) has a role in the treatment of MIDD. 3, 4 We previously reported on a case series in which five of the six patients (83%) treated with HDM/auto-SCT achieved a complete hematological response without any treatment-related mortality or significant morbidity. 3 This case series was updated in 2007, and a complete hematological response was achieved in seven of the eight patients (88%) with a median followup of 17 months (range, 4-41). 1 Here, we report on a longterm hematological and clinical follow-up in patients with MIDD treated with HDM/auto-SCT.
Between 2003 and 2008, 10 patients with MIDD were treated with HDM/auto-SCT at the Boston University Medical Center. Their median age was 45 years (range, 34-70) and nine of the patients were male. Six patients had kappa clonal plasma cell dyscrasia and four patients had lambda clonal plasma cell dyscrasia. The median BM plasma cell percentage before HDM/auto-SCT was 10% (range, 5-30%). Four patients had received treatment previously: one had received bortezomib, one high-dose dexamethasone, one oral melphalan and prednisone, and one thalidomide and dexamethasone. All patients had kidney involvement, two required treatment with chronic dialysis and one had undergone kidney transplantation. Two patients (20%) had cardiac involvement. Among the non-dialysis-dependent patients (n ¼ 8), the median serum creatinine level was 3.1 mg/dL (range, 1.1-4.9) and the median creatinine clearance was 28.5 mL/min (range, 19-128). The median 24-h urine total protein excretion for the whole group of patients was 4037 mg (range, 458-15 632).
The PBSCs were collected as described previously. 3 Six patients received a full-dose of i.v. melphalan at 200 mg/m 2 . Four patients received a modified dose of melphalan at 100-140 mg/m 2 . There were no treatment-related deaths.
The median follow-up of surviving patients is now 40 months (range, 10-78). Six months after HDM/auto-SCT, one patient died from disease progression. On applying an intention-to-treat analysis, six patients (60%) achieved a hematological CR and three patients (30%) achieved a hematological PR, as defined in our previous reports. 1, 3 Median survival has not yet been reached, as nine patients were alive at the time of this report.
Of note, we have now observed that four of the six patients who achieved a CR (67%) had a hematological relapse, occurring at a median of 3 years (range, 2-6). A subset analysis suggests a correlation of the durability of hematological response with the dose of melphalan. Other factors, such as previous treatment, subtype of the light chain, age, plasma cell burden and creatinine clearance, did not correlate with the duration of hematological response. Three of the four patients with a hematological relapse had subsequent bortezomib-based treatment with a complete hematological response again, 5 although the follow-up was short after this treatment.
During the peri-transplant period, two patients required initiation of chronic dialysis. Among the six patients without dialysis dependence, measurements obtained at 2-year follow-up showed a reduction in median urinary protein excretion from 4.91 g/24 h to 0.17 g/24 h (Figure 1) , and an increase in median creatinine clearance from 33 to 50 mL/min. The creatinine clearance and proteinuria remained stable while patients were in hematological response and worsened with hematological relapse. Two patients underwent kidney transplantation and had no evidence of recurrent disease in the renal allograft at 1 and 5 years. One of the two patients with cardiac involvement had a 450% reduction in serum concentration of the brain natriuretic peptide.
HDM/auto-SCT is a safe and effective treatment for MIDD, with 60% of patients achieving a hematological CR. However, 67% of these patients experienced a hematological relapse at a median of 3 years after HDM/ auto-SCT. Of the four patients who received a modified dose of melphalan, two achieved a hematological CR, but all four had hematological and clinical relapses by 2 years. Hematological responses to HDM/auto-SCT in patients with MIDD were reported in other series as well. The median follow-up times in these two other series were 31.7 months (n ¼ 6) 6 and 23.6 months (n ¼ 7). 7 In these two series, there were two patients with hematological relapses after HDM/auto-SCT, with a longer follow-up of 31.7 months. There were no cases of hematological relapses reported in the series with a shorter follow-up of 23.6 months.
In summary, the accumulation of additional cases and the longer follow-up in our series allow us to confirm some previous observations about the disease, add some additional ones and draw some conclusions. First, as previously reported, compared with patients with organized fibrillar light-chain deposition due to AL amyloidosis, patients with MIDD are more predominantly males and are more likely to have a clone consisting of a kappa light chain. Patients with MIDD tolerate HDM/auto-SCT well and have an excellent hematological response rate (90% CR þ PR), but their responses are less durable than those of patients with AL amyloidosis. 8 Nonetheless, their survival is excellent, and this treatment is likely to have an ongoing role in the treatment of MIDD in selected patients. Owing to its rarity, multi-center studies will be needed to define the optimal sequence of treatments for patients with MIDD. Future clinical trials may examine the role of bortezomib as an induction therapy, as a second-line therapy at relapse or as a maintenance therapy to maximize remission duration, protect organ function and optimize survival. 
